Author

E. R. Woodruff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

B. G. Bitler· 3 shared K. R. Jordan· 2 shared Z. L. Watson· 2 shared A. D. Jeong· 1 shared B. R. Corr· 1 shared C. A. Bailey· 1 shared C. Bailey· 1 shared E. Chuong· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. G. Bitler

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Claudin-4 modulates autophagy via SLC1A5/LAT1 as a tolerance mechanism for genomic instability in ovarian cancer.

F. R. Villagomez, J. Lang, P. Webb, M. Neville, E. R. Woodruff, B. G. Bitler

This study shows claudin-4 promotes genomic instability tolerance in ovarian cancer by linking cell junctions to autophagy via SLC1A5/LAT1, and targeting it enhances PARPi efficacy.

bioRxiv · Jan 18, 2024 · PreprintCancer Biology

Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer

B. R. Corr, M. R. Moroney, E. R. Woodruff, Z. L. Watson, K. R. Jordan, T. Danhorn, C. Bailey, R. J. Wolsky, B. G. Bitler

This paper evaluates SM08502, a CLK/DYRK inhibitor, as a single-agent and in combination with paclitaxel for CTNNB1-mutated endometrial cancer, showing synergistic effects and tumor volume reduction in vitro and in vivo.

bioRxiv · Apr 4, 2023 · PreprintCancer Biology

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models

L. L. Nguyen, Z. L. Watson, R. Ortega, E. R. Woodruff, K. R. Jordan, R. Iwanaga, T. M. Yamamoto, C. A. Bailey, A. D. Jeong, S. Guntupalli, K. Behbakht, V. Gibaja, N. Arnoult, E. Chuong, B. G. Bitler

bioRxiv · Feb 23, 2023 · PreprintCancer Biology